$QSI

H.C. Wainwright reiterated a Buy rating and $4.00 price target for Quantum-Si Inc. (QSI), citing product progress. QSI reported Q3 fiscal 2026 results, addressing instrument variability and completing design activities. The company expects first instruments in Q4 fiscal 2026. QSI posted a smaller-than-expected loss of $0.10 per share but missed revenue estimates, reporting $210,000 vs. $280,000 expected. The stock trades at $1.27, with a Fair Value estimate of $1.33.

Quantum-Si (QSI) reported Q3 earnings, highlighting progress on its Proteus platform and amino acid detection. The company expects to demonstrate detection of all 20 amino acids by late 2026 and has started a pre-order program. It reduced 2026 expense guidance and maintains sufficient capital for operations until Q4 2028. Supply chain risks are being mitigated. Proteus launch is planned for Q2 2027.

Quantum-Si (QSI) announced the launch of Proteus in Q2 2027 and reduced its 2026 adjusted operating expense guidance to $87M or less. CEO Jeffrey Hawkins highlighted the company's focus on Proteus readiness, launch preparation, and cash preservation, noting that instrument variability issues have been addressed.

Quantum-Si (QSI) reported Q3 EPS of -$0.10, beating estimates by $0.02, but revenue of $210K missed expectations of $280K. The stock is up 43.66% over 3 months but down 29.09% year-over-year. InvestingPro rates its financial health as 'fair performance'.

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update Proteus ™ remains on track for anticipated Q2 2027 commercial launch BRANFORD, Conn., November 5, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” o

Quantum-Si (QSI) aims to lead the 'post-genomic era' with its Proteus protein sequencing platform, which detected 19 amino acids by October 2026. The company delayed Proteus' commercial launch to Q2 2027 but reported positive test results. QSI shares rose 26.36% year-to-date to $1.39, despite a 33.17% drop over the past year. The company posted a net loss of $101.34m in 2025 and expects $1m revenue in 2026. Analysts see potential upside, with a $4.00 price target.

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Other Events. Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement BRANFORD, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or the “Company”), a proteomics company redefining protein analysis through single-molecule protei

Quantum-Si (QSI) announced it has met Nasdaq's minimum bid price requirement, with its share price staying above $1 for 10 consecutive days. The company's shares fell 1.42% on the news. Quantum-Si previously reported a GAAP EPS of -$0.11 and revenue of $0.34M, both beating estimates.

Neuralink, a private brain-computer interface (BCI) company, successfully helped a patient with ALS communicate. Investors cannot buy Neuralink, but two public companies, Quantum-Si (QSI) and Butterfly Network (BFLY), are connected to the BCI field. QSI makes research tools and saw a 7x volume spike, while BFLY supplies ultrasound chips to BCI developers like Merge Labs and Bridge Neurotech.

Quantum-Si (QSI) shares rose 27.87% after announcing its Proteus protein sequencer can now identify 19 of 20 amino acids. CEO Jeff Hawkins called this an important step toward detecting all 20 by year-end 2026. The company aims for a commercial launch in Q2 2027. Founder JM Rothberg, who owns shares, praised the progress on social media.